Tumor marker–guided precision BNCT for CA19-9–positive cancers: a new paradigm in molecularly targeted chemoradiation therapy

Malignancies with elevated CA19-9 expression, such as pancreatic, biliary, and ovarian cancers, are associated with poor prognosis and limited response to current therapies. This study presents a tumor marker-guided strategy for boron neutron capture therapy (BNCT) by leveraging CA19-9 glycan biology to enable selective tumor targeting via fucose-BSH, a novel boron compound. Through transcriptomic data mining and preclinical validation, fucose-BSH demonstrated LAT1-independent boron delivery, potent BNCT-mediated cytotoxicity, and tumor-specific accumulation in CA19-9-positive models. These findings support a precision chemoradiation approach that addresses a critical gap in BNCT applicability, offering a clinically actionable pathway for patient stratification and therapeutic development in CA19-9-expressing cancers.

Authors

Institutions

Publication Details

Journal
Journal of Translational Medicine
Published
2025-12-08
DOI
https://doi.org/10.1186/s12967-025-07349-7
Citations
1
Primary Topic
Boron Compounds in Chemistry
Type
article
Field-Weighted Citation Impact
1.36

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tumor marker–guided precision BNCT for CA19-9–positive cancers: a new paradigm in molecularly targeted chemoradiation therapy

Takeshi Takarada, Kazuyoshi Gotoh, Yoshinori Sakurai, Noriyuki Kanehira et al.
1 citations
Journal of Translational Medicine
Boron Compounds in Chemistry
1.36
article

Tumor marker–guided precision BNCT for CA19-9–positive cancers: a new paradigm in molecularly targeted chemoradiation therapy

Takeshi Takarada, Kazuyoshi Gotoh, Yoshinori Sakurai, Noriyuki Kanehira, Hiroyuki Michiue, Tatsunori Osone, Kunitoshi Shigeyasu, Akira Morihara, Tomoyuki Tajima, Mizuki Kitamatsu, Takuya Fujimoto, Toshiyoshi Fujiwara, Fuminori Teraishi, Natsuko Kondo, Yutaka Takaguchi, Keiko Kamei, Minoru Suzuki, Taiga Fujita, Narikazu Nagahisa
article en
1 citations

Abstract

Malignancies with elevated CA19-9 expression, such as pancreatic, biliary, and ovarian cancers, are associated with poor prognosis and limited response to current therapies. This study presents a tumor marker-guided strategy for boron neutron capture therapy (BNCT) by leveraging CA19-9 glycan biology to enable selective tumor targeting via fucose-BSH, a novel boron compound. Through transcriptomic data mining and preclinical validation, fucose-BSH demonstrated LAT1-independent boron delivery, potent BNCT-mediated cytotoxicity, and tumor-specific accumulation in CA19-9-positive models. These findings support a precision chemoradiation approach that addresses a critical gap in BNCT applicability, offering a clinically actionable pathway for patient stratification and therapeutic development in CA19-9-expressing cancers.

Journal of Translational MedicineVol. 23(1)
Okayama University of Science (JP), Okayama University (JP), Kyoto University (JP), Okayama University Hospital (JP), University of Toyama (JP), Kindai University (JP)
Japan Society for the Promotion of Science
Openalex Percentile: Top 14%
Boron Compounds in Chemistry
1.36
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.